Dave Feldman

Author's posts

LMHR Case Study – Genetics

In our recent Lean Mass Hyper-Responder (LMHR) case report, we performed extensive genetic testing on the subject, LM, and activity sought input from clinicians and geneticists outside the research team. Because of the broad nature of our testing and absence of notable findings, as determined by expert consultants, and manuscript length limitations, we stated in …

Continue reading

New LMHR Case Study Published

We’re happy to announce the release of our new LMHR Case Study this week in Frontiers in Endocrinology. Feel free to download the PDF and share the page link if you find the paper compelling. (The more our work is shared, the more it supports our efforts, of course.) Highlights of the new paper: LDL-C …

Continue reading

Help Us Raise $46,000 for the LMHR Study

Hello everyone and Happy New Year! We’ve been quite proud of how well we’ve set up efficient budgeting with our research partners for this important study. Lundquist and our bloodwork providers are providing strong discounts along with Keto Mojo and GB HealthWatch completely contributing their products and services. Unfortunately, there’s one area of cost we …

Continue reading

Blasting Off Into 2022

Make no mistake, 2021 has been a watershed year for us. There have been many substantial developments both in what has been completed and what has just begun. New Research Spotlight for Siobhan Huggins Early in the year my colleague, Siobhan Huggins was diagnosed with Lipedema and quickly shifted focus to this and related conditions. …

Continue reading

BREAKING: Our Paper on Low Carb, LDL Cholesterol, and the LMHR Phenotype is Now Available

IMPORTANT UPDATE 1-28-2022: Our paper is now finalized with this guest post from Nick Norwitz now fully updated. Thanks again to the many wonderful readers who contributed their efforts in our final edit. The final version of the Lean Mass Hyper-Responder (LMHR) paper was just released! I’m pleased to report that, even in the early …

Continue reading